Modality
Vaccine
MOA
KRASG12Ci
Target
APOC3
Pathway
RAS/MAPK
PAHBCC
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Jun 2029
Phase 3Current
NCT04140654
171 pts·PAH
2025-09→2028-04·Completed
NCT07584245
1,211 pts·PAH
2020-11→2025-12·Terminated
NCT05217714
208 pts·PAH
2017-04→2026-02·Recruiting
+1 more trial
3,951 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-12-273mo agoPh3 Readout· PAH
2026-02-251mo agoPh3 Readout· PAH
2028-04-162.0y awayPh3 Readout· PAH
2029-06-113.2y awayPh3 Readout· PAH
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Recruit…
P3
Termina…
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2025-12-27 · 3mo ago
PAH
Ph3 Readout
2026-02-25 · 1mo ago
PAH
Ph3 Readout
2028-04-16 · 2.0y away
PAH
Ph3 Readout
2029-06-11 · 3.2y away
PAH
RecruitingCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04140654 | Phase 3 | PAH | Completed | 171 | CfB |
| NCT07584245 | Phase 3 | PAH | Terminated | 1211 | LiverFat |
| NCT05217714 | Phase 3 | PAH | Recruiting | 208 | ACR20 |
| NCT06799279 | Phase 3 | PAH | Completed | 2361 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |